Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Gold, David V ^a   Newsome, Guy ^a   Liu, Donglin ^b   Goldenberg, David M ^a,b  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IMMUNOMEDICS INC   (United States)

Author keywords

Clivatuzumab; Early detection; Enzyme immunoassay; MUC5AC; PAM4; Pancreatic cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CLIVATUZUMAB; MONOCLONAL ANTIBODY; MUCIN 1; MUCIN 3; MUCIN 4; MUCIN 5AC; PAM 4; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; ENZYME IMMUNOASSAY; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; TANDEM REPEAT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, IMMOBILIZED; ANTIBODIES, MONOCLONAL; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; EPITOPE MAPPING; HUMANS; IMMUNOASSAY; MICE; MICE, NUDE; MUCIN 5AC; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS;

EID: 84887711873     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-143     Document Type: Article

References (28)

1. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004, 4(1):45-60. 10.1038/nrc1251, 14681689.
2. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009, 9(12):874-885. 10.1038/nrc2761, 2951677, 19935676.
3. Rachagani S, Torres MP, Moniaux N, Batra SK. Current status of mucins in the diagnosis and therapy of cancer. Biofactors 2009, 35(6):509-527. 10.1002/biof.64, 2846533, 19904814.
4. Ringel J, Lohr M. The MUC gene family: their role in the diagnosis and early detection of pancreatic cancer. Mol Cancer 2003, 2:9-13. 10.1186/1476-4598-2-9, 149423, 12556240.
5. Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, Buchler MW, Aubert JP, Batra SK. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 2001, 7(12):4033-4040.
6. Torres MP, Chakraborty S, Souchek J, Batra SK. Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des 2012, 18(17):2472-2481. 10.2174/13816128112092472, 3530894, 22372499.
7. Schmid BC, Rudas M, Fabjani G, Speiser P, Kaserer K, Leodolter S, Zeillinger R. Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast. Oncol Rep 2003, 10(6):1981-1985.
8. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep 2006, 7(6):599-604. 10.1038/sj.embor.7400705, 1479595, 16741504.
9. Yue T, Goldstein IJ, Hollingsworth MA, Kaul K, Brand RE, Haab BB. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics 2009, 8(7):1697-1707. 10.1074/mcp.M900135-MCP200, 2709194, 19377061.
10. Haab BB, Porter A, Yue T, Li L, Scheiman J, Anderson MA, Barnes D, Schmidt CM, Feng Z, Simeone DM. Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg 2010, 251(5):937-945. 10.1097/SLA.0b013e3181d7738d, 3713623, 20395854.
11. Jass JR, Allison LJ, Edgar SG. Distribution of sialosyl Tn and Tn antigens within normal and malignant colorectal epithelium. J Pathol 1995, 176(2):143-149. 10.1002/path.1711760207, 7636624.
12. Cao Y, Schlag PM, Karsten U. Immunodetection of epithelial mucin (MUC1, MUC3) and mucin-associated glycotopes (TF, Tn, and sialosyl-Tn) in benign and malignant lesions of colonic epithelium: apolar localization corresponds to malignant transformation. Virchows Arch 1997, 431(3):159-166. 10.1007/s004280050083, 9334836.
13. Gold DV, Hollingsworth P, Kremer T, Nelson D. Identification of a human pancreatic duct tissue-specific antigen. Cancer Res 1983, 43(1):235-238.
14. Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer 1994, 57(2):204-210. 10.1002/ijc.2910570213, 7512537.
15. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 2007, 13(24):7380-7387. 10.1158/1078-0432.CCR-07-1488, 18094420.
16. Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, Hruban RH, Goldenberg DM. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2010, 19(11):2786-2794. 10.1158/1055-9965.EPI-10-0667, 2976815, 20810605.
17. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006, 24(2):252-258.
18. Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer 2013, 119(3):522-528. 10.1002/cncr.27762, 22898932.
19. Gulec SA, Cohen SJ, Pennington KL, Zuckier LS, Hauke RJ, Horne H, Wegener WA, Teoh N, Gold DV, Sharkey RM, Goldenberg DM. Treatment of advanced pancreatic carcinoma with 90Y-clivatuzumab tetraxetan: a phase I single-dose escalation trial. Clin Cancer Res 2011, 17(12):4091-4100. 10.1158/1078-0432.CCR-10-2579, 21527562.
20. Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, ONeil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, Goldenberg DM. Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial. Cancer 2012, 118(22):5497-5506. 10.1002/cncr.27592, 22569804.
21. Reis CA, David L, Nielsen PA, Clausen H, Mirgorodskaya K, Roepstorff P, Sobrinho-Simoes M. Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody. Int J Cancer 1997, 74(1):112-121. 10.1002/(SICI)1097-0215(19970220)74:1<112::AID-IJC19>3.0.CO;2-H, 9036879.
22. Nollet S, Forgue-Lafitte ME, Kirkham P, Bara J. Mapping of two new epitopes on the apomucin encoded by MUC5AC gene: expression in normal GI tract and colon tumors. Int J Cancer 2002, 99(3):336-343. 10.1002/ijc.10335, 11992401.
23. Nollet S, Escande F, Buisine MP, Forgue-Lafitte ME, Kirkham P, Okada Y, Bara J. Mapping of SOMU1 and M1 epitopes on the apomucin encoded by the 5' end of the MUC5AC gene. Hybrid Hybridomics 2004, 23(2):93-99. 10.1089/153685904774129694, 15165482.
24. Lidell ME, Bara J, Hansson GC. Mapping of the 45 M1 epitope to the C-terminal cysteine-rich part of the human MUC5AC mucin. FEBS J 2008, 275(3):481-489. 10.1111/j.1742-4658.2007.06215.x, 18167142.
25. Gold DV. Reply to the Letter to the Editor by BARA et al. Clin Cancer Res 2008, 14(16):5306-5307.
26. Sipos B, Möser S, Kalthoff H, Török V, Löhr M, Klöppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003, 442(5):444-452.
27. Bara J, Gautier R, Mouradian P, Decaens C, Daher N. Oncofetal mucin M1 epitope family: characterization and expression during colonic carcinogenesis. Int J Cancer 1991, 47(2):304-310. 10.1002/ijc.2910470222, 1988372.
28. Lidell ME, Hansson GC. Cleavage in the GDPH sequence of the C-terminal cysteine-rich part of the human MUC5AC mucin. Biochem J 2006, 399(1):121-129. 10.1042/BJ20060443, 1570170, 16787389.